Candidate Molecules definition

Candidate Molecules means, collectively, monoclonal antibody ("mAb") HUIV26 and mAb HUI77 as provided by Bio-Management to Ixsys hereunder.
Sample 1Sample 2Sample 3

Examples of Candidate Molecules in a sentence

  • Ixsys shall optimize and humanize the Candidate Molecules as set forth in the Research Plan.

  • The goal of the Program is: (a) humanize and optimize Candidate Molecules, and (b) to perform certain preclinical development.

  • SANOFI By: /s/ Xxxx Xxxxxxxx By: /s/ [*] Printed Name: Xxxx Xxxxxxxx Printed Name: [*] Title: CEO Title: [*] Date: 9/7/2018 Date: 7/8/2018 Exhibit 1 Feasibility Study Agreement Candidate Molecules Molecule No 1 [*] Molecule No 2 [*] Molecule No 3 [*] Molecule No 4 [*] Molecule No 5 [*] Molecule No 6 [*] Molecule No 7 [*] Annex 2 Press Release Dyadic International, Inc.

  • CMI shall have the right (in its sole discretion), exercisable by giving AME express written notice of such exercise prior to August 15, 2000, to extend the Program Term with respect to the following Candidate Molecules: mAb XL313 and mAb FM155, for the period commencing on the date within ninety (90) days following the date AME timely receives such notice of exercise from CMI and continuing for the subsequent seven (7) months.

  • Bio-Management shall pay to Ixsys *** each for the humanization and optimization of each of the two (2) Candidate Molecules, to be paid *** starting from the Effective Date.

  • Ixsys shall not use the Program Antibodies, or the suboptimized and humanized compositions of matter derived by Ixsys from the Candidate Molecules under the Program (or the cDNA encoding such compositions of matter), for any purpose other than the performance of its obligations under this Agreement.

  • No other license or rights, including without limitation any license or rights in Materials, Candidate Molecules or Program Antibodies, shall be granted or created by implication, estoppel or otherwise.

  • Bio-Management shall pay to Ixsys [***] each for the humanization and optimization of each of the two (2) Candidate Molecules, to be paid in equal quarterly installments over the six (6) months starting from the Effective Date.

  • AME shall not use the Program Antibodies, or the suboptimized and humanized compositions of matter derived by AME from the Candidate Molecules under the Program (or the cDNA encoding such compositions of matter), for any purpose other than the performance of its obligations under this Agreement.

  • Bio-Management shall have the right (in its sole discretion), exercisable by giving Ixsys express written notice of such exercise not less than thirty (30) days prior to the expiration of the Program Term, to extend the Program Term with respect to the following Candidate Molecules: mAb XL313 and mAb FM155, for the period commencing on the date ninety (90) days following the date Ixsys timely receives such notice of exercise from Bio-Management and continuing for the subsequent seven (7) months.

Related to Candidate Molecules

  • Collaboration Compound means any of the following: (a) FG-4592, (b) any HIF Compound (other than FG-4592) that is added to this Agreement pursuant to Section 3.6, and (c) any salts, esters, complexes, chelates, crystalline and amorphous morphic forms, pegylated forms, enantiomers (excluding regioisomers), prodrugs, solvates, metabolites and catabolites of any of the foregoing ((a) or (b)).

  • Development Candidate means a Compound that meets the Development Candidate Criteria for the initiation of a Development Program for the treatment of CF, and which is the subject of a notice from Vertex to CFFT that Vertex intends to commence formal pre-clinical development of the Compound in the Field pursuant to the provisions of Section 3.1 hereof.

  • Product Candidate means each of MYO-101, MYO-102, MYO-103, MYO-201 and MYO-301, as defined on Exhibit B, in each case in any form or formulation.

  • Lead Compound means any compound of lead other than galena which, when treated in the manner described below, yields to an aqueous solution of hydrochloric acid a quantity soluble lead compound exceeding, when calculated as lead monoxide, five percent of the dry weight of the portion taken analysis.

  • Collaboration Target means the Initial Collaboration Targets set forth on Exhibit F and any Additional Target or Substitute Target that is selected in accordance with Section 3.3 of this Agreement.

  • Licensed Compound means [***].

  • Licensed Compounds means any EZH2 Compound(s) that is:

  • Compounds means a small molecule HMT inhibitor.

  • Antibody means a molecule or a gene encoding such a molecule comprising or containing one or more immunoglobulin variable domains or parts of such domains or any existing or future fragments, variants, modifications or derivatives thereof.

  • Diagnostic Product means any test or assay for diagnosing or detecting a disease, disorder, medical condition, or symptom.

  • Collaboration Product means any pharmaceutical product in finished form that contains a Collaboration Compound, either as the sole active ingredient or in combination with one or more other active ingredients, and all present and future formulations, dosages and dosage forms thereof.

  • Compound means the taking of two or more ingredients and fabricating them into a single

  • Gene Therapy means a product or service for the treatment or prevention of a disease that utilizes ex vivo or in vivo delivery (via viral or nonviral gene transfer methods or systems) of Genetic Material, including any cell incorporating Genetic Material.

  • Phase I Study means a study in humans which provides for the first introduction into humans of a product, conducted in healthy volunteers or patients to obtain information on product safety, tolerability, pharmacological activity or pharmacokinetics, as more fully defined in 21 C.F.R. § 312.21(a) (or the non-United States equivalent thereof).

  • Commercialization or “Commercialize” means any and all activities undertaken at any time for a particular Licensed Product and that relate to the manufacturing, marketing, promoting, distributing, importing or exporting for sale, offering for sale, and selling of the Licensed Product, and interacting with Regulatory Authorities regarding the foregoing.

  • Antigen means a substance recognized by the body as being foreign; it results in the production of specific antibodies directed against it.

  • Clinical Studies means any clinical studies of a Licensed Product conducted on humans.

  • Phase I Clinical Study means, as to a particular Licensed Product, an initial clinical study in humans with the purpose of assessing the Licensed Product’s safety, tolerability, toxicity, pharmacokinetics or other pharmacological properties.

  • Clinical Study or “Clinical Studies” means a Phase 0 Xxxxx, Xxxxx 0 Xxxxx, Xxxxx 0 Trial or Phase 4 Trial, or such other study in humans that is conducted in accordance with good clinical practices and is designed to generate data in support or maintenance of an NDA, MAA or other similar marketing application.

  • Nicotine product means a product that contains nicotine and is not any of the following:

  • Biological product means a virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, protein other than a chemically synthesized polypeptide, or analogous product, or arsphenamine or any derivative of arsphenamine or any other trivalent organic arsenic compound, applicable to the prevention, treatment, or cure of a disease or condition of human beings.

  • Biological Samples means any physical samples obtained from Study Participants in accordance with the Protocol for the purposes of the Study.

  • Phase IIb Clinical Trial means a clinical trial of a Product on sufficient numbers of patients that is designed to provide a preliminary determination of safety and efficacy of such Product in the target patient population over a range of doses and dose regimens.